Industry News

The collaboration will embed AI-driven modeling into Repligen’s tangential flow filtration systems to speed process development, according to the companies.

The $2 million expansion builds on global investments to meet growing demand for analytical and cold-chain services, according to the CDMO.

The expansion will make the Aachen, Germany-based biotech the largest producer of Human Platelet Lysate and create new skilled jobs in the region, according to the company.

The deal marks Barcelona-based Esteve’s entry into the U.S. market for small-molecule API development and manufacturing.

The proposed deal would expand Switzerland-based Sandoz’s in-house biosimilar development and continuous manufacturing capabilities.

Part of its CRDMO Hub, the 30,000-square-meter building will be one of the world’s largest modular biologics DP facilities, according to the company.

The CDMO’s retroviral vector will be used to manufacture AvenCell’s investigational dual-targeted therapy for B cell malignancies and autoimmune diseases.

The partnership uses biomanufacturing and flow chemistry to onshore U.S. supplies of critical medicines.

The facility will expand production of Planova filters to meet rising demand in biopharma manufacturing, according to the company.

The move reportedly strengthens Ofichem’s position in the Nordic region and complements its recent acquisition of formulation specialist Avivia.

The company is expanding multisite peptide and oligonucleotide production capacity to meet demand across its pipeline.

The newly acquired site near Simtra’s existing facility in Bloomington, Indiana offers more than 300,000 square feet of expansion space.

The CDMO introduced new research offerings and expanded production capacity, while also advancing digital and sustainability initiatives.

The 200,000-square-foot facility will serve as a regional hub, offering increased production capacity and local support for pharmaceutical customers in Asia.

The company said it is expanding its cGMP manufacturing footprint and AI-powered development systems to strengthen domestic production of essential medicines.

The $200M expansion projects will focus on its Fishers, Indiana and Cisterna di Latina sites to meet demand for biologics-related manufacturing.

The Morrisville site will support US biopharma clients with formulation and particle analysis services.

The new platform will support formulation development for poorly soluble drug candidates and create research and development jobs in Killorglin, said the company.

The North Carolina facility features cleanrooms, injection molding, and lab services tailored to the healthcare sector, according to the company.

The biotech company plans to expand fill-finish, automation and antisense oligonucleotide capabilities at its Research Triangle Park site.

The company says global market conditions led to the decision to halt one of two planned projects in Kanagawa Prefecture.

Regulatory clearance for WuXi’s first pre-filled syringe facility signals continued momentum in global manufacturing expansion, according to the CRDMO.

The 154,000-square-foot Bedford site will offer flexible, capital-efficient space for clinical and commercial life sciences manufacturing, according to the company.

The CDMO will provide end-to-end cell line development and clinical manufacturing support at sites in Seattle, Washington and Chiba, Japan, for Okayama University.

A new high-speed filling line in Mississauga, Ontario will support production of up to 15 million units annually and boost capacity for dermatologic products.

The agreement between the biotech company and CDMO provides GMP-compliant U.S. production ahead of planned Phase IIb trials.

The multiyear expansion will add new production, R&D, and quality operations jobs at the company’s Rancho Cucamonga site.

The Ridgefield, New Jersey facility will support both Sanofi production and Thermo Fisher Scientific’s growing pharma and biotech customer base.

The site, part of a €637 million investment in the U.K. and Ireland, features sealed unloading docks to ensure zero time out of refrigeration for temp-sensitive products.

While the financial terms of the private transaction were not disclosed, it is believed to be one of the largest such deals in pharmaceutical services in recent years.